Group 1 - A class action has been filed against Centene Corporation on behalf of investors who acquired its securities between December 12, 2024, and June 30, 2025 [1] - Allegations state that Centene misled investors about its business prospects, creating a false impression of reliable revenue outlook and growth while actual enrollment rates and morbidity were lower than expected [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3] Group 2 - Following the announcement on July 1, 2025, Centene's stock price dropped from $56.65 to $44.78 per share, a decline of over 40% [3] - Shareholders are encouraged to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [4] - Robbins LLP has been dedicated to shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5]

Financial Performance & Growth - Clover Health anticipates insurance revenue of $1.8 billion to $1.875 billion for full year 2025[50] - The company projects Adjusted EBITDA between $50 million and $70 million for full year 2025[9, 50] - Clover Health expects a 32% year-over-year increase in Medicare Advantage (MA) membership in 2025[9, 44] - Clover Health's Insurance Benefits Expense Ratio (BER) for the first half of 2025 was 87.3%[24] Clover Assistant & Clinical Outcomes - Clover Assistant (CA) is associated with earlier diagnosis of Chronic Kidney Disease (CKD) by approximately 18 months on average[18] - Clover Assistant is associated with 15% lower all-cause hospitalizations and 18% lower 30-day readmissions for members with Chronic Obstructive Pulmonary Disease (COPD)[18, 20] - Clover Health achieved a 4.94 out of 5 Stars on HEDIS measures for Star Rating year 2025, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide[18] Strategic Initiatives - Clover Health is focused on a ~$500 billion market with over 35 million seniors enrolled in Medicare Advantage[8] - Clover Health's Counterpart Health subsidiary aims to expand the company's care model to more plans and providers[8] - Approximately 97% of Clover Health's membership is enrolled in PPO plans[8, 49]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores categorize stocks into four main types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes finding undervalued stocks based on financial ratios [3] - Growth Score focuses on a company's financial health and future growth potential [4] - Momentum Score capitalizes on existing trends in stock prices and earnings [5] - VGM Score combines the strengths of all three Style Scores to identify the most attractive investment opportunities [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in stock selection [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [9] Stock Example: Humana Inc. (HUM) - Humana Inc. is a major health care plan provider in the U.S., offering various health insurance products [11] - Currently rated 3 (Hold) by Zacks, Humana has a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [12] - Recent analyst revisions have increased Humana's earnings estimate for fiscal 2025, with a consensus estimate of $16.93 per share and an average earnings surprise of +9.6% [12] - Given its solid Zacks Rank and favorable Style Scores, Humana is recommended for investors' consideration [13]

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/centene-corporation-lawsuit-submi ...

Group 1 - UnitedHealth Group is experiencing its worst performance since 2008, with the stock down approximately 50% this year, closely approaching the 2008 decline of -54.3% [1] Group 2 - The investment strategy focuses on GARP (growth at a reasonable price) stocks while also seeking opportunities in other areas, with no specified time horizon for investments [2] - The analyst has developed market-beating algorithms using Python to identify attractive investment opportunities within their portfolio [2] - The analyst has experience working at TipRanks as an analysis/news writer and editor, which has enhanced their understanding of market interests and the importance of accurate information [2]

Core Viewpoint - Centene Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between December 12, 2024, and June 30, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Centene's management provided overly positive statements while concealing material adverse facts regarding the company's enrollment and morbidity rates [2]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2]. - Following this announcement, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 8, 2025, to request the Court to appoint them as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Insights - Elevance Health, Inc. (ELV) has experienced a significant decline of 20.3% year to date, underperforming compared to industry peers and the S&P 500 Index [1][7] - The stock closed at $293.99, near the lower end of its 52-week range of $273.71–$567.26, potentially presenting an attractive entry point for value investors [1] - Elevance has a market capitalization of $66.2 billion, with peers like UnitedHealth Group and Centene also facing challenges this year [1] Membership and Revenue Challenges - Medicaid membership has decreased by 15.1% in 2024 and an additional 4.1% in the first half of 2025, impacting revenue [4] - Membership in Medicare Supplement and employer group risk-based segments is also declining, with expectations of continued volatility into 2026 due to recent policy changes [4][6] Rising Costs and Margin Pressure - Medical costs are increasing due to higher utilization, leading to a deterioration in the benefit expense ratio, which worsened by 260 basis points year over year to 88.9% in Q2 [5] - The full-year benefit expense ratio is projected to be around 90%, with expectations of further increases in the second half of the year [5] Analyst Sentiment and Earnings Outlook - Management has revised its full-year 2025 adjusted EPS outlook down to approximately $30, from a previous range of $34.15-$34.85, reflecting a decline from the 2024 figure of $33.04 [6] - Analysts have sharply cut 2025 and 2026 EPS estimates, with the current consensus estimate for 2025 EPS at $30.59, indicating a 7.4% decline from the prior year [9] Valuation Metrics - Elevance Health trades at a forward 12-month P/E of 9.24X, significantly below its five-year median of 13.44X and the industry average of 14.32X, indicating investor caution [10] - Despite a steeper sell-off, peers UnitedHealth and Centene command higher multiples of 14.05X and 9.94X, respectively [10] Long-Term Growth Potential - Elevance has solid long-term growth drivers, including product expansion, revenue diversification, and premium increases, which may help mitigate current pressures [11] - The company is reallocating resources to more profitable areas and has a return on invested capital of 9.36%, outperforming the industry average of 5.80% [12] Shareholder Value Initiatives - Elevance maintains consistent dividend payouts with a yield of 2.33%, higher than the industry average of 1.37% [13] - The company repurchased shares worth $379 million in Q2 2025, with approximately $8 billion remaining under its buyback authorization as of June 30, 2025 [13]

Core Insights - Clover Health Investments, Corp. (NASDAQ: CLOV) reported significant growth in Q2, with an increase in members and revenues, but the stock price fell by up to 30% due to rising medical costs across the industry [1] Company Summary - Clover Health's Q2 earnings demonstrated exponential growth in both membership and revenue [1] - Despite the positive earnings report, the company's stock experienced a substantial decline, attributed to industry-wide increases in medical costs following new implementations [1] Industry Summary - The healthcare industry is facing heightened medical costs, which have negatively impacted stock performance for companies like Clover Health [1]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Group 1 - The company maintains a bullish rating on UnitedHealth Group (NYSE: UNH) due to the addition of 770,000 new members served in Q2 2025 [1] - The analyst emphasizes a high likelihood of continued growth for UNH based on its current performance metrics [1] - The approach taken by the analyst involves breaking down complex financial and technological problems to identify overlooked investment opportunities [1] Group 2 - The analyst has a strong background in investment, private equity, and venture capital, which supports the credibility of the insights provided [1] - The focus of the articles includes emerging technologies, sustainable investing, and the intersection of innovation and finance [1] - The analyst expresses a commitment to sharing insights and learning from fellow investors to drive positive change in the investment landscape [1]